ToxIC Core Registry Sites
The ToxIC Core Registry comprises over 50 locations throughout the U.S., with several international locations also participating. The majority of active U.S. medical toxicology practices and accredited medical toxicology fellowship programs are participating locations.
-
What is Medical Toxicology?
Medical toxicology is a subspecialty of medicine focusing on the diagnosis, treatment, and prevention of poisoning from drugs, environmental and biological toxicants and more.
-
What is ToxIC’s Core Registry?
The Core Registry collects data and detects national trends on exposures to novel opioids and psychostimulants, adverse pharmaceutical events, snakebites, and more.
-
ToxIC Registries and Projects
In addition to the ToxIC Core Registry, the specialized ToxIC Sub-Registries and projects provide data specific to trending research interests in the field of medical toxicology.
-
Publications
Data from ToxIC’s registries and projects is often presented at conferences or published as full length scholarly papers in peer-reviewed high quality medical and scientific journals.
Publication Alerts
-
Journal of Emergency Medicine: “Emergency Department Patients with Para-Fluorofentanyl Overdose”
This study from the ToxIC Fentalog Project examined 833 emergency department patients across 10 U.S. hospitals between 2020 and 2023 with confirmed fentanyl overdoses, focusing on the presence of para-fluorofentanyl (PFF), a rising fentanyl analog. -
JAMA Network Open: “Disparities in Treatment and Referral After an Opioid Overdose Among Emergency Department Patients”
A ToxIC Fentalog Study Group cohort study of 1,683 patients found that Black patients presenting to the emergency department with opioid overdose were significantly less likely to receive outpatient treatment referrals (5.7%) compared to White patients (9.6%). This disparity highlights the need for targeted interventions and improved referral practices to ensure equitable access to follow-up care for all patients. -
Drug and Alcohol Dependence: “Detected substances among patients with confirmed bromazolam exposure who present to the emergency department following a suspected opioid and/or stimulant-related non-fatal overdose”
A study from the ToxIC Drug Overdose Toxico-Surveillance (DOTS) Program investigated the presence and context of bromazolam, an emerging illicit benzodiazepine, among 341 patients treated for non-fatal opioid or stimulant overdoses at 17 U.S. emergency departments. -
Journal of Addiction Medicine: “Geographic Trends in Nonfatal Overdose Involving or Exposed to Opioids and Xylazine Across U.S. Emergency Departments”
ToxIC Fentalog Study of 1,397 patients across 10 sites reveals 1 in 5 patients presenting with opioid-related overdose had cooccurring xylazine exposure. Regional trends highlight the need for tailored public health responses.
News & Announcements
-
Fall Message From ACMT President, Ziad Kazzi, MD, FACMT
“As summer winds down and we head into fall, we are reminded of the season’s themes of change, reflection, and harvest. It’s a fitting time to look back at the many ways our members have contributed to the mission of ACMT and to celebrate those efforts…” -
JMT Special Article: The Value of Medical Toxicologists
This landmark paper documents the value of medical toxicologists in improving patient outcomes, and their positive impact on population health and health care systems. -
A Message From Our President, Ziad Kazzi, MD, FACMT
“Over the next two years of my presidency, I hope to make a meaningful impact and serve your needs to the best of my ability. My “virtual door” is always open to your questions, feedback, and ideas…” -
ToxIC and ACMT Represented at College on Problems of Drug Dependence (CPDD) Annual Meeting
Several members of ACMT’s Toxicology Invesitgators Consortium (ToxIC) presented at the 2025 Annual Meeting for the College on Problems of Drug Dependence (CPDD) in New Orleans, LA. Presentations featured data from recent projects including ToxIC’s FDA-funded Drug Overdose Toxico-Surveillance (DOTS) Reporting Program, and the NIDA-funded Fentanyl Analog (Fentalog) study.